Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 8, 2008--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of several patents. The claims of these patents cover novel immune modulatory oligonucleotides (IMO) and chemical modifications of IMOs, each of which provide unique immune responses.

The issued patents include:

• US 7,354,907, entitled "Short Immunomodulatory Oligonucleotides"

• US 7,329,648, entitled "Modulation of Oligonucleotide CpG-mediated Immune Stimulation by Positional Modification of Nucleosides"

• EP 1322656, entitled "Modulation of Immunostimulatory Activity of Immunostimulatory Oligonucleotide Analogs by Positional Chemical Changes"

• EP 1252307, entitled "Modulation of Oligonucleotide CpG-mediated Immune Stimulation by Positional Modification of Nucleosides"

• AU 2005218065, entitled "Modulation of Oligonucleotide CpG-mediated Immune Stimulation by Positional Modification of Nucleosides"

"The claims of these issued patents provide additional coverage for our expanding portfolio of synthetic DNA-based Toll-like Receptor (TLR)-targeted compounds," said Steven Ritter, Ph.D., J.D., Vice President of Intellectual Property and Contracts. "Our TLR-targeted compounds, agonists and antagonists, are designed using our chemistry-based approach."

Presently, the Company holds over 220 issued patents and pending patent applications world-wide, which cover novel agonists and antagonists of TLRs 7, 8 and 9.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.

Forward Looking Statements

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborations with Novartis, Merck & Co., and Merck KGaA will be successful; whether the patents and patent applications owned or licensed by the Company will protect the Company's technology and prevent others from infringing it; whether the Company's cash resources will be sufficient to fund the Company's operations; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Annual Report on Form 10-K filed on March 11, 2008, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

CONTACT: Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
kluethje@iderapharma.com
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com

SOURCE: Idera Pharmaceuticals, Inc.